Cullinan Therapeutics, Inc. - Common Stock (CGEM)

Q4 2022 13F Holders as of 31 Dec 2022

Type / Class
Equity / Common Stock
Shares outstanding
59,112,975
Total 13F shares
37,711,425
Share change
+629,341
Total reported value
$397,852,399
Put/Call ratio
25%
Price per share
$10.55
Number of holders
94
Value change
+$5,318,094
Number of buys
52
Number of sells
32

Institutional Holders of Cullinan Therapeutics, Inc. - Common Stock (CGEM) as of Q4 2022

As of 31 Dec 2022, Cullinan Therapeutics, Inc. - Common Stock (CGEM) was held by 94 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 37,711,425 shares. The largest 10 holders included BIOIMPACT CAPITAL LLC, BVF INC/IL, CHI Advisors LLC, VANGUARD GROUP INC, BlackRock Inc., AMERICAN INTERNATIONAL GROUP, INC., Nextech Invest Ltd., Boxer Capital, LLC, EcoR1 Capital, LLC, and TANG CAPITAL MANAGEMENT LLC. This page lists 94 institutional shareholders reporting positions in this security for the Q4 2022 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.